There is a merger in cruise brokerage. The two Swiss tourism companies e-hoi and Cruise Center also want to strengthen their bargaining power with the cruise lines. Business, down during the pandemic, is picking up
Valentino, the Italian luxury fashion house, will open a new boutique in Geneva on the prestigious Rue du Rhône. Valentino’s CEO Jacopo Venturini is repositioning the brand, further elevating its couture status and
Vivalto Santé has acquired a majority stake in Groupe CIC Santé as well as a stake in RXPM, a company also entirely owned by Dr. Maire which operates in the field of radiology. Groupe CIC
BlackFin Capital Partners has reported the sale of its portfolio company New Access, a Geneva-based private banking technology firm, to FNZ, a global wealth management platform with registered office in London. The acquisted New Access
Metropolitan Life Global Funding I has issued CHF 175 million Bonds in the form of a Funding Agreement Backed (FAB) bond. Credit Suisse has acted as lead manager, together with BNP Paribas Suisse and Deutsche Bank
Kellerhals Carrard has launched an interdisciplinary Sustainability & ESG Desk becoming a legal partner of the Sustainable Switzerland Initiative of the NZZ. Furthermore, the firm founds a cooperative as an umbrella structure. The new desk
Nevermined, a Web3 company that provides tools to read, write and own your digital assets, has announced its €3 million seed investment round, co-led by Signature Ventures and Polymorphic Capital. MME advised Nevermined on the equity
Swiss software company Netcetera has acquired routeRANK, the Lausanne-based specialist for reliable and environmentally friendly door-to-door route planning. With this strategic transaction, the two companies will provide IT solutions for multimodal mobility worldwide. The newly
The branding agency Intr has recently merged with the agency Staaacks. The merger aims to broaden the profile of the creative and consulting agency. Intr is a Bern-based agency specialising in branding, branded content and
Solvias, an independent pharmaceutical testing and manufacturing company, has acquired Netherlands-based Cergentis to bolster its biologics and cell & gene therapy testing capabilities. Cergentis marks Solvias’ second acquisition since partnering with health care investors Water
